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The Joint European Compound Library:
boosting precompetitive research
Je´re´my Besnard1, Philip S. Jones2, Andrew L. Hopkins1 and Andrew D. Pannifer2,
a.pannifer@dundee.ac.uk
The Joint European Compound Library (JECL) is a new high-throughput screening collection aimed at
driving precompetitive drug discovery and target validation. The JECL has been established with a core
of over 321 000 compounds from the proprietary collections of seven pharmaceutical companies and
will expand to around 500 000 compounds. Here, we analyse the physicochemical profile and chemical
diversity of the core collection, showing that the collection is diverse and has a broad spectrum of
predicted biological activity. We also describe a model for sharing compound information from multiple
proprietary collections, enabling diversity and quality analysis without disclosing structures. The JECL is
available for screening at no cost to European academic laboratories and SMEs through the IMI European
Lead Factory (http://www.europeanleadfactory.eu/).
Background
The decline in the rate of new molecular entity
(NME) discovery is well documented [1] and the
cost of discovering a drug has risen dramatically
over the past 20 years. Boosting precompetitive
research has become a major theme to reverse
this trend by sharing risk in early-stage research
[2,3] and by bringing together key areas of
expertise from diverse organisations. These
precompetitive initiatives have generated highly
successful partnerships such as the Structural
Genomics Consortium and the Human Blood
Plasma Metabolome Consortium, created to
build technology platforms supporting drug
design and development of biomarkers. How-
ever, access by external organisations to the
pharmaceutical companies’ proprietary screen-
ing collections has, until now, been very limited
owing to their high intellectual property value.
The compounds embody a large amount of
in-house molecular design expertise and syn-
thetic effort, and represent a primary source of
future drugs. These very qualities make the
libraries an extremely valuable resource for ac-
ademic groups seeking to identify inhibitors and
tool compounds for their biological targets.
Making compounds from these proprietary li-
braries available to academic laboratories and
small companies has therefore the potential to
expand the pool of pharmacologically validated
drug targets available to the industry and to
identify new lead compounds.
The Joint European Compound Library (JECL)
is a key component of the IMI European Lead
Factory (ELF) and brings together over 321 000
high-quality, drug-like and lead-like compounds
from the in-house collections of seven large
pharmaceutical companies into a single
screening collection. Over the course of the next
four years, the JECL will be expanded through
bespoke synthesis of 200 000 compounds to
address regions of chemical space unexplored or
underrepresented by the core set. These addi-
tional compounds are being designed by in-
dustry and academic scientists and synthesised
by companies across Europe. This collection is
now available to the academic community and
to biotech companies across Europe to be
screened at the ELF (http://www.europeanlead-
factory.eu/). The ELF provides established ex-
pertise in compound logistics, high-throughput
screening and characterisation infrastructure,
and medicinal chemistry for triaging the screen
output. The JECL is also being screened by the
contributing pharmaceutical companies to ex-
tend their existing hit identification campaigns.
In this article, we describe the physicochemical
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profile of the collection, chemical diversity and
pharmacological profile of the core 321 000
compounds currently available for screening. We
also describe a model for assessing diversity of
compounds from multiple collections while
allowing compound structures to remain confi-
dential.
Design of the core collection
A key consideration in combining compound
libraries from different pharmaceutical com-
panies is the degree of overlap between them.
As a result of mergers in the pharmaceutical
industry and consequent merging of screening
collections, it has been possible to gain an
insight into the similarities of proprietary
screening collections. In two published cases
[4,5], the resulting unions of the collections
demonstrated that the identity and chemical
similarity between company collections is very
low. This was shown by Bayer, following its
acquisition of Schering, and also by Johnson
and Johnson (J&J) – finding a similar result
when comparing the 3DPharmaceuticals col-
lection with its existing compound collection.
Very recently, AstraZeneca and Bayer collabo-
rated in a precompetitive initiative to compare
and analyse their entire compound collections
for similarity, with a view to possible compound
exchange [6]. The result was similar to the
previous studies and also showed a low overlap
between these two very large compound col-
lections.
The emerging picture of a low chemical
similarity between the independent screening
libraries suggests that an efficient and cost-
effective way to generate a highly diverse
library would be to combine the libraries from
multiple companies. The combined chemical
space explored by all the collections would be
available and this would maximise the chances
of hits against a novel biological target.
Merging the entire individual collections would
also generate an enormous and financially
‘unscreenable’ library. However, combining
representative subsets from the respective li-
braries is an alternative approach that
would be expected to retain efficient
exploration of chemical space and is a
feasible goal.
Drug-likeness and diversity analysis
Conventional diversity analysis of multiple
compound collections typically involves the
exchange of chemical structures and calculation
of chemical similarity scores based on, for ex-
ample, 2D fingerprints [7,8], BCUT descriptors [9]
or physicochemical properties. Structure ex-
change becomes commercially sensitive when
proprietary compounds are being analysed and,
when multiple companies are involved, the in-
tellectual property issues can become complex.
Comparison of compounds from proprietary
collections is therefore facilitated if disclosure of
the compound structure is not required. To
enable this structure-free comparison, a Pipeline
Pilot protocol calculating 2D fingerprints to-
gether with a large number of physicochemical
parameters was developed at the University of
Dundee and distributed among the pharma-
ceutical companies in the consortium. The pro-
tocol also assigned each compound a unique
identifier. Each company ran the protocol to
calculate the descriptors on an agreed number
of compounds and the results were returned to
Dundee for diversity analysis. This process
ensured that a consistent set of descriptors was
generated to allow comparison and charac-
terisation of the proposed contributions while
maintaining confidentiality. Drug-likeness can
be estimated from a range of properties de-
rived directly from the molecular structure.
These include properties such as topological
polar surface area (TPSA), number of rotatable
bonds, molecular weight (MW) and log P, and
also substructural features (‘structural alerts’)
known to have assay-interfering or toxico-
phoric properties. A desirability index, such as
the QED [10] score, can then be generated as
an estimator of chemical attractiveness. All of
these properties were included in the Pipeline
Pilot protocol.
Diversity analysis requires further information
about compound structures to be disclosed. A
number of properties and descriptors encoding
structural information can be directly derived
from a compound structure and exchanged
between owners of compound collections to
enable chemical diversity calculations. Circular
fingerprints, such as extended connectivity fin-
gerprints (ECFPs), have been shown to be highly
effective in encoding SAR information [7] and are
well suited for estimating chemical similarity in
the context of drug discovery. We chose ECFP6
fingerprints as the principal descriptor of mo-
lecular structure to maintain consistency with
the pharmacological profiling of the JECL pre-
sented in this paper and these were used for
Tanimoto calculations (Box 1). The seven com-
pound collections were then combined and
filtered, to reduce clusters of molecules with a
Tanimoto coefficient of 1 to a single represen-
tative. This fingerprint-based deduplication
could also remove very close analogues. No
company collection was treated as a reference
set and any could be asked to remove their
compound. Once all duplicates had been re-
moved, the final set of just over 321 000 mole-
cules was registered in an Oracle database. A
requirement for all the compounds contributed
by the pharmaceutical companies was that they
were not commercially available.
Analysis of the JECL
The final set of selected compounds was ana-
lysed to profile drug-likeness and diversity. Di-
versity was assessed from a conventional
chemocentric perspective using chemical di-
versity metrics and from a biological perspective.
The spectrum of biological target activity was
assessed using predicted compound activity in
1855 Bayesian activity models built using data in
the ChEMBL database.
Drug-likeness and physicochemical profile
The key descriptors summarising the physico-
chemical properties of the library are shown in
Fig. 1a–e. With the compounds all originating in
the collections of pharmaceutical companies, it
comes as no surprise that the collection has an
attractive profile and is overwhelmingly within
the Lipinski parameters for MW and log P. The
fraction of sp3-hybridised carbon atoms (Fsp3)
indicates a broad spread of hybridisation from
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BOX 1
Tanimoto similarity
2D fingerprints are a representation of a molecular structure in which the structure is
decomposed in silico into a set of substructural features. The similarity of a pair of molecules
can then be calculated by counting the number of features in common compared with the
features present in either molecule but not in both. This similarity score is known as
Tanimoto similarity. In this analysis extended connectivity fingerprints (ECFP6) were used.
These fingerprints represent the molecule as a set of substructures centred on each atom in
the molecule with the substructures extending up to three bonds away from the centre
atom.
Tanimoto similarity is defined as C/(A + B + C) where C = number of fingerprint features
present in both molecules, A = number of fingerprint features in molecule A and not in B,
and B = number of fingerprint features in molecule B and not in A.
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molecules rich in planar, aromatic moieties to
very sp3-rich molecules with greater 3D char-
acteristics.
Chemical diversity
The chemical diversity of the JECL was analysed
through two different methods. First, the Tani-
moto similarity of each compound with its
nearest neighbour was calculated and plotted in
a histogram (Fig. 1f ). The profile demonstrates a
diverse set with a mode Tanimoto similarity of
0.6 for each compound to its nearest neighbour.
Of particular interest for the JECL is the rela-
tionship between the individual company
subsets and the regions of chemical space oc-
cupied by these subsets. Do the subsets rep-
resent different areas of chemical space or are
the compounds from each subset randomly
distributed with respect to each other? To ad-
dress this question, the same nearest neighbour
diversity calculation was performed for each
pairwise combination of the seven company
subsets (intersubset diversity) and within each
subset (intrasubset diversity). The seven intra-
subset diversities define the profile of nearest
neighbours within a subset whereas the 21
pairwise intersubset diversities identify the
nearest neighbours of compounds in one subset
in each of the other subsets. The histograms
profile these nearest neighbour distributions
and the results of this are shown in Fig. 2. The
intrasubset diversities are shown along the
leading diagonal and it is apparent that the
diversity within each company subset is similar
apart from in one case where the distribution of
the maximum Tanimoto similarity is right- rather
than left-skewed. The mode values for the
intrasubset similarity are in the 0.6–0.7 range,
with the exception of Co7 which has a very
diverse subset with a similarity mode value at
0.3. This 0.6–0.7 similarity value is very close to
that in the histogram of the entire JECL and
suggests that the nearest neighbour of each
JECL compound is mainly derived from the
same company subset. Analysis of the inter-
subset histograms confirms this. The intersubset
similarity histograms all have a very different
profile from the intrasubset histograms. The
intersubset histograms are all shifted well to the
left with the most frequent nearest neighbours
in the 0.2–0.3 range, demonstrating that the
nearest neighbours between subsets are sub-
stantially less similar than nearest neighbours
within subsets. In all cases, the intersubset di-
versities are all greater than the seven intra-
subset diversities. Again, this is consistent with
the Bayer–Schering, J&J–3DP and Bayer–Astra-
Zeneca results. Closer comparison with the
Bayer–AstraZeneca results shows that the nearest
neighbour similarities of the intersubset com-
parisons are lower than seen in the comparison of
the full Bayer–AstraZeneca collections. This is
likely to be caused by the very different sizes of
the compound subsets being compared and the
consequent lower likelihood of a near neighbour
being in the contributed subsets.
Second, the number of unique ECFP6 finger-
print features in each of the seven company
subsets was calculated and normalised to the
size of the subset to generate another measure
of diversity. The number of unique ECFP6 fea-
tures reflects the number of unique substruc-
tural features in the subset and, by normalising
for the number of compounds, a measure of
diversity is obtained. The fingerprint diversities
of these subsets were then compared with the
diversity of the JECL. To do this, the JECL was
randomly subsetted into seven groups, corre-
sponding in size to the company subsets, and
the normalised unique ECFP6 feature counts
were calculated for each subset. Boxplots were
then generated for the seven company subsets
and the seven randomly selected JECL subsets
to summarise the distribution of the ECFP6
counts. These boxplots are shown in Fig. 3.
The subsets generated from the combined JECL
have a significantly higher number of ECFP6
Drug Discovery Today  Volume 20, Number 2  February 2015 PERSPECTIVE
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FIGURE 1
Key physicochemical parameters and diversity of the Joint European Compound Library (JECL). The key physicochemical parameters of (a) a log P, (b) topological
polar surface area (TPSA), (d) molecular weight (MW), (e) fraction sp3 carbon atoms and (c) the QED desirability score are typical of a lead-like library and centred
around a MW of 350 Da and a log P of 2–3. The fraction of sp3-hybridised carbon atoms indicates a broad spread of 3-dimensionality. (f) The nearest neighbour
diversity of the collection using Tanimoto similarity with extended connectivity fingerprint (ECFP)6.
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features per compound than the individual
subsets and demonstrate the efficiency of
combining subsets from different sources to
generate diversity.
Biological activity diversity
The key aim for the JECL is to generate hit
molecules in a target-agnostic manner against a
wide range of biological targets. We were
therefore interested to understand the spectrum
of target classes where the JECL was likely to
generate biologically active molecules. Because
the compounds have no publically available
biological data associated with them, the pre-
dicted activity for each compound against a
panel of Bayesian models was calculated.
Bayesian activity models use machine learning
methods and the structures of known active and
inactive molecules from biological screens to
derive an activity model and predict activity of
compounds untested in these assays. The higher
the score a compound has in a Bayesian model
for a given biological target the higher is the
likelihood that the compound will be active
against that target. These approaches have been
PERSPECTIVE Drug Discovery Today Volume 20, Number 2  February 2015
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FIGURE 2
A matrix of nearest neighbour histograms showing diversity within the individual seven subsets (intrasubset diversity) along the leading diagonal; and pairwise
similarities between subsets (intersubset diversity) in the off-diagonal cells. Intrasubset diversity is consistently lower than intersubset diversity.
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FIGURE 3
The normalised extended connectivity fingerprint ECFP6 count (y axis) in the Joint European Compound
Library (JECL) and the contributing subsets. The number of normalised unique ECFP6 features in seven
randomly selected subsets from the JECL is shown in the boxplot on the left. The number of normalised
unique ECFP6 features in the seven individual company subsets is shown on the right. The increase in
feature counts in the JECL demonstrates the effectiveness of combining subsets to increase diversity.
Boxplots were generated in R.
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demonstrated to be effective in chemogenomic
analyses to predict unknown biological activity
[11,12]. Bayesian activity models for 1855 diverse
biological targets were built using data from the
ChEMBL17 database [13,14]. Only data from
published literature were used to generate the
models. Compounds with fewer than four atoms
and greater than 650 Da MW were excluded
from model building and the threshold for ac-
tivity was set to a pXC50 of 5. Targets with at least
ten active compounds were retained and the
predicted activity profile of each compound in
the JECL against this panel of models was cal-
culated. The top predicted targets were also
mapped to their target class (e.g. kinase, ion
channel or phosphatase) for global analysis of
target spectrum. Leave-one-out cross-validation
used in the generation of each model was used
to calculate a threshold between predicted ac-
tivity and inactivity by minimising false-positive
and -negative rates. This threshold was used to
define a minimum score for activity and, if the
top score of a compound failed to meet the
model threshold, it was assigned to the ‘Low
Score’ category. This ensures that only predic-
tions within the domain of the model are used
and all compounds with low confidence or low
predictions are assigned to this Low Score cat-
egory.
Table 1 shows the classification by target class
used in the Bayesian analysis. The classification is
in two hierarchical levels derived from the
ChEMBL database. The top level L1 class is very-
high-level whereas the L1_L2 classification
breaks this further into enzyme types. The
number of biological targets and the number of
experimental bioactivities associated with each
target class is shown. Fig. 4 shows two pie charts
demonstrating the predicted activity of the JECL
in these target classes. The first pie chart shows
the activity of the JECL in the very-high-level L1
target classification whereas the second shows
predicted activities in the L1_L2 classification.
These charts indicate a very general, target-ag-
nostic collection suitable for screening against a
wide range of target classes and with a high
likelihood of generating bioactives in key phar-
maceutically relevant target classes such as G-
protein-coupled receptors (GPCRs), kinases and
proteases.
In addition to providing a screening library,
the ELF provides a full infrastructure for com-
pound storage, screening, characterisation and
hit triage. A key component of this infrastruc-
ture is the Honest Data Broker (HDB). The HDB is
a secure cloud-based repository for all the
compound and assay information generated by
ELF projects and also provides a triaging inter-
face to allow a final list of hit compounds to be
generated. Central to this triage model is a
granular set of permissions allowing carefully
controlled access to the molecular structures by
the triage team. These permissions maintain
compound confidentiality while supporting the
scientific requirements of an HTS triage. The
HDB also provides functionality to reorder
compounds for dose–response and further
characterisation of hits such as analytical
chemistry. Projects from academic and SME
partners are prosecuted in close collaboration
with expert biology, chemistry and computa-
tional scientists at the European Screening
Centre with the final aim of building a high-
quality hit list.
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TABLE 1
The level 1 (L1) classification of target classes according to ChEMBL17 and L1_L2 shows
the further breakdown of this classification into subclasses.
Number of targets Number of bioactivities
L1_class
Enzyme 1712 282 085
Membrane receptor 336 206 678
Ion channel 156 30 472
Transporter 59 20 426
Unclassified 424 18 800
Transcription factor 56 17 613
Cytosolic other 54 8486
Membrane other 8 1036
Structural 7 876
Secreted 27 848
Adhesion 8 570
Nuclear other 6 408
Surface antigen 12 322
L1_L2_class
Membrane receptor_7TM1 261 187 915
Enzyme_kinase 448 98 943
Enzyme_protease 218 66 782
Enzyme_ND 833 51 932
Ion channel 156 30 472
Transporter 59 20 426
Unclassified 424 18 800
Transcription factor 56 17 613
Enzyme_reductase 40 17 294
Enzyme_hydrolase 24 12 668
Enzyme_lyase 17 11 361
Membrane receptor_ND 37 9488
Enzyme_cytochrome P450 35 8603
Cytosolic other 54 8486
Enzyme_phosphodiesterase 28 6928
Membrane receptor_7TM3 14 4540
Membrane receptor_7TM2 19 4083
Enzyme_phosphatase 35 3233
Enzyme_transferase 14 2466
Enzyme_isomerase 10 1148
Membrane other 8 1036
Structural 7 876
Secreted 27 848
Adhesion 8 570
Enzyme_NTPase 6 485
Membrane receptor_7TMFZ 1 449
Nuclear other 6 408
Surface antigen 12 322
Membrane receptor_Toll-like and interleukin (Il)-1 1 139
Enzyme_ligase 2 137
Enzyme_aminoacyltransferase 1 78
Membrane receptor_phosphatase 1 51
Enzyme_electrochemical 1 27
Membrane receptor_kinase 1 10
Membrane receptor_7TMTAS2R 1 3
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Concluding remarks
The JECL is a high-quality and diverse library with
predicted activity against a wide range of bio-
logical targets, including classes that have been
rich in therapeutically relevant targets. The value
and efficiency of combining collections to gen-
erate diversity is clear from the analysis of
intersubset and intrasubset diversity where the
intersubset diversity demonstrates that each
collection is derived from a distinct region of
chemical space. It is also clear that the similarity
between any pairwise combination of the seven
company collections is low, and it is likely that
any company seeking to increase the diversity of
its screening library efficiently would benefit
from a compound exchange.
The JECL is now available to academic labo-
ratories and biotech companies for screening
their targets, and expert characterisation, me-
dicinal chemistry and modelling resource is also
available to follow up the screen output. The
collection will also be screened by the contrib-
uting pharmaceutical companies and provides
them with a cost-effective model to explore
additional chemical space beyond their own
compound collections and to augment existing
screening campaigns. The JECL provides a model
for further precompetitive collaboration and
represents a major step forwards in the level of
collaboration between large pharmaceutical
companies and also between commercial
organisations and the European academic
community. The importance of linking academic
investigators with pharmaceutical screening li-
braries and expertise is also recognised in the
recent announcement of the AstraZeneca–MRC
collaboration in which up to 15 academic drug
discovery programmes will be screened against
the AstraZeneca compound collection, and also
in the GlaxoSmithKline (GSK) Openlab Initiative.
These growing partnerships will be crucial for
translating the wealth of academic early-stage
target validation into tangible patient benefits.
Acknowledgements
The ELF is funded with financial support from IMI
JU Grant Agreement 115489. The EFPIA partners
contributing compounds are AstraZeneca, Bayer,
Janssen Pharmaceutica, H. Lundbeck, Merck,
Sanofi-Aventis Deutschland and UCB Pharma.
References
1 Bunnage, M.E. (2011) Getting pharmaceutical R&D back
on target. Nat. Chem. Biol. 7, 335–339
2 Mittleman, B. et al. (2013) Precompetitive consortia in
biomedicine – how are we doing? Nat. Biotechnol. 31,
979–985
3 Sidders, B. et al. (2014) Precompetitive activity to
address the biological data needs of drug discovery.
Nat. Rev. Drug Discov. 13, 83–84
4 Schamberger, J. et al. (2011) Rendezvous in chemical
space? Comparing the small molecule compound
libraries of Bayer and Schering. Drug Discov. Today 16,
636–641
5 Engels, M.F. et al. (2006) A cluster-based strategy for
assessing the overlap between large chemical libraries
and its application to a recent acquisition. J. Chem. Inf.
Model. 46, 2651–2660
6 Kogej, T. et al. (2013) Big pharma screening collections:
more of the same or unique libraries? The AstraZeneca-
Bayer Pharma AG case. Drug Discov. Today 18, 1014–
1024
7 Rogers, D. and Hahn, M. (2010) Extended-connectivity
fingerprints. J. Chem. Inf. Model. 50, 742–754
8 Willett, P. (2011) Similarity searching using 2D structural
fingerprints. Methods Mol. Biol. 672, 133–158
9 Pearlman, R. and Smith, K.M. (1998) Novel software
tools for chemical diversity. Persp. Drug Discov. Design
9–11, 339–353
10 Bickerton, G.R. et al. (2012) Quantifying the chemical
beauty of drugs. Nat. Chem. 4, 90–98
11 Glick, M. et al. (2006) Prediction of biological targets for
compounds using multiple-category Bayesian models
trained on chemogenomics databases. J. Chem. Inf.
Model. 46, 1124–1133
12 Martinez-Jimenez, F. et al. (2013) Target prediction for
an open access set of compounds active against
Mycobacterium tuberculosis. PLoS Comput. Biol. 9,
e1003253
13 Gaulton, A. et al. (2012) ChEMBL: a large-scale
bioactivity database for drug discovery. Nucleic Acids
Res. 40, D1100–D1107
14 Bento, A.P. et al. (2014) The ChEMBL bioactivity
database: an update. Nucleic Acids Res. 42, D1083–
D1090
Je´re´my Besnard1
Philip S. Jones2
Andrew L. Hopkins1
Andrew D. Pannifer2
1College of Life Sciences, University of Dundee,
Dow Street, Dundee, DD1 5EH Scotland, UK
2College of Life Sciences, University of Dundee,
Biocity Scotland, Bo’ness Road, Newhouse, ML1
5UH Scotland, UK
PERSPECTIVE Drug Discovery Today Volume 20, Number 2  February 2015
L1 Class repartition
Enzyme
L1 and L2 class repartition
Ion channel
Ion channel
Membrane receptor
Transporter
Unclassified
Transcription factor
Cytosolic other
Membrane other
Structural
Secreted
Adhesion
Nuclear other
Surface antigen
NA
Lawscore
Lawscore
Other
Membrane receptor_7TM1
Enzyme_kinase
Enzyme_protease
Enzyme_NA
Drug Discovery Today 
FIGURE 4
The pie charts show the predicted activities in the ChEMBL17 Bayesian models. In each chart, the top predicted targets for each compound are mapped to their
target class. In the L1_L2 chart pie-chart slices of <5% of the total are merged into the ‘Other’ category. Compounds where highest prediction failed to meet
minimum threshold in every model were assigned to the ‘Low Score’ category.
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